Drug Chatter -- Tracking biopharma stock chatter

DrugPatentWatch - Biopharmaceutical Business Intelligence

Profile for Acceleron Pharma Inc. (XLRN)

« Back to company index

XLRN Chatter Timeline

Stock Ticker for XLRN

Most Active Tweeters for XLRN

UserTweets
@Tickeron 10
@1MinuteStock 7
@Gambiste1 6
@StckPro 4
@otcdynamics 3

Recent Tweets for XLRN

IlliniJJ @IlliniJJ
$XLRN - Announced it will host a webcast and conference call on Tuesday, December 10, 2019 at 6:00 a.m. EST to revi… https://t.co/n78Tnl28Cz
December 6th 2019, 5:12pm
Gambiste1 @Gambiste1
RT @BioRunUp: $XLRN $BMY - FDA AdCom on 12/18 no longer required. PDUFA still 4/4/20
December 6th 2019, 2:12pm
1MinuteStock @1MinuteStock
Wondering about risks of $XLRN? The 21-day volatility is 19.71% https://t.co/JXwt944IOs
December 6th 2019, 12:12pm
SwingTradeBot @SwingTradeBot
Recent $XLRN technical alerts: NR7 plus 7 more alerts... https://t.co/9CITuDOmfh
December 6th 2019, 12:12pm
Biotech2050 @Biotech2050
Congrats $XLRN @AcceleronPharma $BMY @ScienceAtBMS No adcom required for luspatercept! https://t.co/YJMLcTNlXT
December 6th 2019, 12:12pm
AlertTrade @AlertTrade
DOWNSIDE MOMENTUM ALERT: $XLRN Acceleron Pharma, Inc ? TradeIdeas via https://t.co/VS8RO1bzXJ to FREE Trading Room
December 6th 2019, 12:12pm
StckPro @StckPro
$BMY $XLRN NEW ARTICLE : No Ad Com review for Bristol-Myers' luspatercept for MDS https://t.co/Bry4m0mGr6 Get all t… https://t.co/MW4n0KcnEg
December 6th 2019, 12:12pm
NateNs5 @NateNs5
? No Ad Com review for Bristol-Myers' luspatercept for MDS $BMY $XLRN https://t.co/TPVqA8zuFd
December 6th 2019, 12:12pm
pnani456 @pnani456
$XLRN $BMY Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® ...… https://t.co/dNkagwiwzk
December 6th 2019, 12:12pm
MarketCurrents @MarketCurrents
$BMY $XLRN - No Ad Com review for Bristol-Myers' luspatercept for MDS https://t.co/YTvakZMTT3
December 6th 2019, 12:12pm
BioRunUp @BioRunUp
$XLRN $BMY - FDA AdCom on 12/18 no longer required. PDUFA still 4/4/20
December 6th 2019, 12:12pm
Sports_bios @Sports_bios
@bradloncar Too crazy - prolly someone hit the wrong buttons.. the only thing $XLRN and $BMY (ex-CELG) has in commo… https://t.co/TmkhrNDs0b
December 6th 2019, 9:12am
otcdynamics @otcdynamics
$XLRN Acceleron Appoints Global Innovation and Drug Development Executive Kemal Malik, MB BS, to its Board of https://t.co/Tr3Of3lrqc
December 6th 2019, 8:12am
bradloncar @bradloncar
This is weird news for $XLRN to be emailing out. How's that Celgene/Bristol integration going?… https://t.co/oJ5PXxtcQN
December 5th 2019, 4:12pm
Tickeron @Tickeron
$XLRN in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators:… https://t.co/HWcWKeDxxJ
December 5th 2019, 4:12pm
OlympiaReport @OlympiaReport
Acceleron Pharma Inc $XLRN Receives Consensus Rating of “Buy” from Analysts https://t.co/td8wRkPcgh
December 4th 2019, 10:12pm
WeekHerald @WeekHerald
Brokerages Set Acceleron Pharma Inc $XLRN Target Price at $58.70 https://t.co/Uu0ylIeimJ
December 4th 2019, 10:12pm
newsfilterio @newsfilterio
Acceleron Named a “Most Honored” Company in Institutional Investor 2020 “All-America Executive Team” Rankings $XLRN https://t.co/u8T0BnjFAw
December 4th 2019, 8:12pm
rungirl1104 @rungirl1104
Congratulations to $XLRN on this well deserved recognition https://t.co/2IXl7XIaZt
December 4th 2019, 6:12pm
otcdynamics @otcdynamics
$XLRN Acceleron Named a “Most Honored” Company in Institutional Investor 2020 “All-America Executive Team” Rankings https://t.co/iIxxcYugGz
December 4th 2019, 4:12pm
ByJoFagg @ByJoFagg
December 18 advisory committee meetings announced for #luspatercept in myelodysplastic syndrome $BMY $XLRN and… https://t.co/YEf0vJy7WL
December 4th 2019, 11:12am
Biotech2050 @Biotech2050
Ccredit Suisse on $BMY partner $XLRN https://t.co/q6GShhOOTR
December 3rd 2019, 11:12pm
Gambiste1 @Gambiste1
RT @TradeFlags: #GoldenCross $XLRN at 48.84 R15 HiLo 66% T1Y 59 buy fwdPE -23.0 DIV N/A #Acceleron #stocks #trading #finance #market http…
December 3rd 2019, 10:12pm
TradeFlags @TradeFlags
#GoldenCross $XLRN at 48.84 R15 HiLo 66% T1Y 59 buy fwdPE -23.0 DIV N/A #Acceleron #stocks #trading #finance… https://t.co/Kb6Yf0M5wp
December 3rd 2019, 9:12pm
Gambiste1 @Gambiste1
RT @StckPro: $XLRN NEW ARTICLE : Stock Upgrades: Acceleron Pharma Shows Rising Relative Strength https://t.co/VN5fJCUdMS Get all the latest…
December 3rd 2019, 1:12pm
StckPro @StckPro
$XLRN NEW ARTICLE : Stock Upgrades: Acceleron Pharma Shows Rising Relative Strength https://t.co/VN5fJCUdMS Get all… https://t.co/VfeOZPaqxi
December 3rd 2019, 11:12am
NateNs5 @NateNs5
FDA Ad Com set for Bristol-Myers' luspatercept for MDS $BMY $XLRN https://t.co/IgotHqeafh
December 3rd 2019, 10:12am
Gambiste1 @Gambiste1
RT @1stOncology: #Acceleron to Host Conference Call and Webcast to Review Data Presented at #ASH19 $XLRN https://t.co/AU8gB8dwxL
December 3rd 2019, 10:12am
Gambiste1 @Gambiste1
RT @Pelion2001: @BioStocks Last earnings call management anticipated a panel due to new mechanism of action so no surprise $XLRN
December 3rd 2019, 10:12am
NedPagliarulo @NedPagliarulo
FDA will hold an adcomm to review $BMY and $XLRN drug Reblozyl for its second indication in myelodysplastic syndrom… https://t.co/KmG61Tc7Eu
December 3rd 2019, 9:12am
StckPro @StckPro
$BMY $XLRN NEW ARTICLE : FDA Ad Com set for Bristol-Myers' luspatercept for MDS https://t.co/nhTHIu7uxD Get all the… https://t.co/3N2DQrfzWN
December 3rd 2019, 9:12am
MarketCurrents @MarketCurrents
$BMY $XLRN - FDA Ad Com set for Bristol-Myers' luspatercept for MDS https://t.co/pipgn5wvBc
December 3rd 2019, 9:12am
1stOncology @1stOncology
#Acceleron to Host Conference Call and Webcast to Review Data Presented at #ASH19 $XLRN https://t.co/AU8gB8dwxL
December 3rd 2019, 9:12am
Pelion2001 @Pelion2001
@BioStocks Last earnings call management anticipated a panel due to new mechanism of action so no surprise $XLRN
December 3rd 2019, 9:12am
semodough @semodough
RT @BioStocks: $BMY & $XLRN Announce FDA Advisory Committee Will Review Reblozyl (luspatercept-aamt) for Use in Patients With Myelodysplast…
December 3rd 2019, 8:12am
BioStocks @BioStocks
$BMY & $XLRN Announce FDA Advisory Committee Will Review Reblozyl (luspatercept-aamt) for Use in Patients With Myel… https://t.co/KONvfIcFPh
December 3rd 2019, 7:12am
Gambiste1 @Gambiste1
RT @the_chart_life: $XLRN Acceleron Pharma ...I like it as long as it can stay above ~$48. https://t.co/53fFUbgxdt
December 2nd 2019, 10:12pm
the_chart_life @the_chart_life
$XLRN Acceleron Pharma ...I like it as long as it can stay above ~$48. https://t.co/53fFUbgxdt
December 2nd 2019, 10:12pm
DataTrials @DataTrials
$XLRN Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease…NCT03124459. Estimated Primary Completion Date - 01/2020
December 2nd 2019, 8:12pm
ConsumerFeed @ConsumerFeed
Acceleron Pharma Inc $XLRN Given Consensus Rating of “Buy” by Brokerages https://t.co/uB9BPwDK0D
December 2nd 2019, 5:12pm
bbnsnews @bbnsnews
Acceleron Pharma Inc $XLRN Receives $58.70 Consensus Target Price from Analysts https://t.co/uHXSGRhTNN
December 2nd 2019, 5:12pm
Tickeron @Tickeron
$XLRN in Downtrend: its price expected to drop as it breaks its higher Bollinger Band on November 25, 2019. View od… https://t.co/m5NvXzdfnd
December 2nd 2019, 2:12pm
CentralChartsEN @CentralChartsEN
$XLRN #ACCELERONPHARMA - Daily: @AcceleronPharma ACCELERON PHARMA INC. is part of a very strong bullish trend. Trad… https://t.co/gW61t0ixCO
December 2nd 2019, 2:12pm
Londinia_IA @Londinia_IA
$XLRN #ACCELERONPHARMA - Daily: ACCELERON PHARMA INC. is part of a very strong bullish trend. Traders may consider… https://t.co/ztNmdDiI78
December 2nd 2019, 2:12pm
AlertTrade @AlertTrade
UPSIDE MOMENTUM ALERT: $XLRN Acceleron Pharma, Inc ? TradeIdeas via https://t.co/VS8RO0TZ6b to FREE Trading Room
December 2nd 2019, 2:12pm
StckPro @StckPro
$TRV $XLRN NEW ARTICLE : Travelers Poised To Continue Its Impressive Streak Of Dividend Hikes https://t.co/oand15MJT2
December 2nd 2019, 9:12am
SeekingAlpha @SeekingAlpha
$XLRN - Acceleron Heads Toward Commercial Success. Continue reading: https://t.co/rdj96Jm8r8 #investing #stocks #finance
December 2nd 2019, 9:12am
otcdynamics @otcdynamics
$XLRN Acceleron to Host Conference Call and Webcast to Review Data Presented at the 61st American Society of https://t.co/RgvfAIk2Wb
December 2nd 2019, 7:12am
TekATL3 @TekATL3
$XLRN breaking higher here, good follow through and should break 60
December 2nd 2019, 7:12am
parthar @parthar
@BioBreakout Isn’t the $XLRN decision already out ?
December 1st 2019, 10:12pm

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2019. All rights reserved.